hVIVO Plc
http://hvivo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From hVIVO Plc
World’s Largest Commercial Human Challenge Trials Unit Launched To Keep Up With Growing Demand
A UK-based CRO specializing in human challenge trials says there is a big shift in industry sentiment towards such studies. Companies targeting infectious diseases are now actively accommodating challenge trials in their development plans instead of needing persuasion.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
Podcast: hVIVO's Andrew Catchpole On Human Challenge Studies, From COVID-19 To Malaria
hVIVO, a specialist contract research organization, performs human challenge trials, helping pharma companies develop vaccines with greater efficiency. Chief scientific officer Andrew Catchpole recently spoke with In Vivo about what it takes to perform an effective human challenge study, how they keep study participants safe, and how the company is helping address the ongoing scourge of malaria.
Australian Biotech Hopes Nasal Spray Can Alter Course Of COVID-19 Spread
ENA Respiratory expects its "preventive" nasal spray, which primes innate immunity against respiratory viruses including SARS-CoV-2, to play a meaningful role in protecting at-risk populations and lowering community transmission of COVID-19. It plans to explore the potential of the broad-spectrum antiviral immunomodulator in other areas, including COPD, and wider partnering opportunities.
Company Information
- Industry
- Services
- Other Names / Subsidiaries
-
- Imutex Limited
- Open Orphan plc
- Retroscreen Virology Group plc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice